ORPHA:180275
Paget disease of the nipple
Also known as: Mammary Paget disease · Paget disease of the breast · Paget's disease of the nipple
Publications
994
75.8th percentile
Trials
2
Interventional, condition-specific
Researchers
998
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Paget disease of the nipple describes a rare presentation of breast cancer, seen most frequently in women aged 50-60, manifesting with nipple drainage and itching, erythema, crusty and excoriated nipple, thickened plaques, and hyperpigmentation (less frequently). It is due to tumor cells invading the nipple-areola complex and represents 1-3% of all new breast cancer diagnoses.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015873
- UMLS:C1704323
- NCIT:C3301
Additional Mondo synonyms (2)
Paget's disease of nipple · nipple Paget's disease
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
994 matched papers (301 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
994
994 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
994 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
301 in the last 10 years · high confidence · 75.8th percentile (publications denominator)
Phrase hits: 994 · MeSH hits: 0
Who's working on it?
998
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01
- 02Cantisani C3 papers · 2025
UOC of Dermatology, Policlinico Umberto I Hospital, Sapienza Medical School of Rome, 00161 Roma, Italy.
Papers in Europe PMC - 03Caruso G3 papers · 2025
Unit of Cellular Pathology, San Filippo Neri Hospital of Rome, 00135 Roma, Italy.
Papers in Europe PMC - 04
- 05Longo C3 papers · 2025
Department of Dermatology, University of Modena and Reggio Emilia, 41121 Modena, Italy.
Papers in Europe PMC - 06Pellacani G3 papers · 2025
UOC of Dermatology, Policlinico Umberto I Hospital, Sapienza Medical School of Rome, 00161 Roma, Italy.
Papers in Europe PMC - 07
- 08Taliano A3 papers · 2025
UOC of Dermatology, Policlinico Umberto I Hospital, Sapienza Medical School of Rome, 00161 Roma, Italy.
Papers in Europe PMC - 09Akay BN2 papers · 2025
Faculty of Medicine, Department of Dermatology, Ankara University, Ankara, Turkey.
Papers in Europe PMC - 10Bang Dalen CE2 papers · 2026
Department of Pathology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; none in our sample are currently recruiting. 12 trials are registered for Paget disease, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
high confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: Paget disease
12
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT03713203·RECRUITING·PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).
Not reviewed·Conditions: Paget Disease of the Vulva · Paget Disease, Extramammary·Matched via name phrase
- NCT06791070·RECRUITING·A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum
Not reviewed·Conditions: Paget Disease, Extramammary · Scrotum Disease·Matched via name phrase
- NCT06683846·RECRUITING·Ivonescimab in the Treatment of Multiple Advanced Tumors
Not reviewed·Conditions: Pheochromocytoma/Paraganglioma · Rhabdomyosarcoma · Paget Disease, Extramammary · Renal Angiomyolipoma·Matched via name phrase
- NCT06684327·RECRUITING·Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Not reviewed·Conditions: Paget Disease, Extramammary · Rhabdomyosarcoma · Testicular Cancer · Penile Cancer·Matched via name phrase
- NCT05859074·RECRUITING·A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Not reviewed·Conditions: Cutaneous Squamous Cell Carcinoma · SCC - Squamous Cell Carcinoma · Basal Cell Carcinoma · BCC·Matched via name phrase
- NCT07117851·RECRUITING·A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease
Not reviewed·Conditions: Extramammary Paget Disease · Scrotum Disease·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 6 · after dedupe 6 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 6 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (6)
- isrctn·ISRCTN45106315·No longer recruiting·A randomised controlled trial of duct endoscopy as an adjunct to standard surgery for pathological nipple discharge
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN47734678·No longer recruiting·BASO II: a randomised trial for the management of small well-differentiated and special type carcinomas of the breast
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN43697410·No longer recruiting·Scottish Chemo-Endocrine Trial D
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99513870·No longer recruiting·United Kingdom randomised trial for the management of screen-detected ductal carcinoma in situ (DCIS) of the breast
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN68177645·No longer recruiting·A collaborative trial to evaluate the role of radiotherapy and adjuvant tamoxifen in the conservative management of clinical stage I and II breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36585784·Recruiting·ATNEC - Axillary management in T1-3N1M0 breast cancer patients with needle biopsy-proven nodal metastases at presentation after neoadjuvant chemotherapy
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Paget disease of the nipple — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Paget disease of the nipple" OR "Paget disease of nipple" OR "Mammary Paget disease" OR "Paget disease of the breast" OR "Paget disease of breast" OR "Paget's disease of the nipple" OR "Paget's disease of nipple" OR "nipple Paget's disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Paget disease of the nipple" OR "Paget disease of nipple" OR "Mammary Paget disease" OR "Paget disease of the breast" OR "Paget disease of breast" OR "Paget's disease of the nipple" OR "Paget's disease of nipple" OR "nipple Paget's disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"Paget disease"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:05:28.817Z
